The C-reactive protein/albumin (CRP/Alb) ratio has been reported as a prognostic factor of survival for patients with a variety of cancers. However, its prognostic impact for advanced cancer patients receiving palliative care remains presently unknown.
Objective:
The present study assessed the prognostic value of the CRP/Alb ratio, and compared this with that of the Glasgow Prognostic Score (GPS) and Palliative Prognostic Index (PPI) in a cohort of advanced cancer patients receiving palliative therapy.
Methods:
The medical records of 262 eligible patients who died of advanced cancer from February 1, 2013 to December 30, 2017 in the palliative care unit of the Fudan University Shanghai Cancer Center were retrospectively reviewed for the analysis.
Results:
The present results revealed that a CRP/Alb ratio ≥1.31 (hazard ratio [HR], 2.33 [1.78–3.05], p < 0.001) can predict poor prognosis through univariate analysis. In addition, the multivariate analysis revealed that CRP/Alb (HR, 2.09 [1.54–2.84], p < 0.001), GPS (HR, 1.81 [1.07–3.07], p < 0.001), and PPI (HR, 3.35 [2.25–4.99], p < 0.001) were all independent prognosis factors. To compare the discriminatory performance of the CRP/Alb ratio with that of other established prognostic indexes in palliative care settings, the c-statistics, integrated discriminatory improvement index, net reclassification index, and receiver operating characteristic curves were generated, and it was demonstrated that the CRP/Alb ratio (c-statistics, 0.64 [0.61–0.68]) was able to discriminate advanced cancer patients with different survivals, with analogous discriminatory ability as GPS (c-statistics, 0.63 [0.59–0.66]) and PPI (c-statistics, 0.64 [0.60–0.68]). Notably, the combination of multiple prognostic indexes exerted higher discriminatory ability, compared with any single predictive index (c-statistics, 0.69 [0.66–0.73], p < 0.001).
Conclusions:
The present study suggests that the CRP/Alb ratio is a promising prognostic factor in predicting cancer patient survival in palliative care settings. Incorporating both objective parameters and the subjective index may improve the prediction accuracy of prognosis.
Get full access to this article
View all access options for this article.
References
1.
AdamsE, BoultonM, WatsonE: The information needs of partners and family members of cancer patients: A systematic literature review. Patient Educ Couns, 2009; 77:179–186.
2.
SteinhauserKE, ChristakisNA, ClippEC, et al.: Preparing for the end of life: Preferences of patients, families, physicians, and other care providers. J Pain Symptom Manage, 2001; 22:727–737.
3.
KirkP, KirkI, KristjansonLJ: What do patients receiving palliative care for cancer and their families want to be told? A Canadian and Australian qualitative study. BMJ, 2004; 328:1343.
4.
GlareP, VirikK, JonesM, et al.: A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ, 2003; 327:195–198.
5.
ChristakisNA, LamontEB: Extent and determinants of error in doctors' prognoses in terminally ill patients: Prospective cohort study. BMJ, 2000; 320:469–472.
6.
AllinKH, NordestgaardBG: Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci, 2011; 48:155–170.
7.
SuhSY, AhnHY: A prospective study on C-reactive protein as a prognostic factor for survival time of terminally ill cancer patients. Support Care Cancer, 2007; 15:613.
8.
von MeyenfeldtM: Cancer-associated malnutrition: An introduction. Eur J Oncol Nurs, 2005; 9:S35–S38.
9.
GuptaD, LisCG: Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr J, 2010; 9:69.
10.
Alberici PastoreC, Paiva OrlandiS, GonzálezMC: Association between an inflammatory-nutritional index and nutritional status in cancer patients. Nutr Hosp, 2013; 28:188–193.
11.
RoxburghCS, McMillanDC: Cancer and systemic inflammation: Treat the tumour and treat the host. Br J Cancer, 2014; 110:1409–1412.
12.
MetgudR, PatelS: Serum and salivary levels of albumin as diagnostic tools for oral pre-malignancy and oral malignancy. Biotech Histochem, 2014; 89:8–13.
13.
KinoshitaA, OnodaH, ImaiN, et al.: The reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol, 2015; 22:803–810.
14.
GioulbasanisI, PallisA, VlachostergiosPJ, et al.: The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer. Lung Cancer, 2012; 77:383–388.
15.
MeekCL, WallaceAM, ForrestLM, et al.: The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer. Clin Nutr, 2010; 29:206–209.
16.
LeungEY, ScottHR, McMillanDC: Clinical utility of the pretreatment Glasgow Prognostic Score in patients with advanced inoperable non-small cell lung cancer. J Thorac Oncol, 2012; 7:655–662.
17.
WeiXL, WangFH, ZhangDS, et al.: A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: The C-reactive protein/albumin ratio. BMC Cancer, 2015; 15:350.
18.
ZhouT, ZhanJ, HongS, et al.: Ratio of C-reactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer. Sci Rep, 2015; 5:10481.
19.
XuXL, YuHQ, HuW, et al.: A novel inflammation based prognostic score, the C-reactive protein/albumin ratio predicts the prognosis of patients with operable esophageal squamous cell carcinoma. PLoS One, 2015; 10:e0138657.
20.
ParkHC, KimMY, KimCH: C-reactive protein/albumin ratio as prognostic score in oral squamous cell carcinoma. J Korean Assoc Oral Maxillofac Surg, 2016; 42:243–250.
21.
ShibutaniM, MaedaK, NagaharaH, et al.: Prognostic significance of the preoperative ratio of C-reactive protein to albumin in patients with colorectal cancer. Anticancer Res, 2016; 36:995–1001.
22.
LiuX, SunX, LiuJ, et al.: Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol, 2015; 8:339–345.
23.
WuM, GuoJ, GuoL, et al.: The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer. Tumour Biol, 2016; 37:12525–12533.
24.
HarukiK, ShibaH, ShiraiY, et al.: The C-reactive protein to albumin ratio predicts long-term outcomes in patients with pancreatic cancer after pancreatic resection. World J Surg, 2016; 40:2254–2260.
25.
LeeJM, LeeHS, HyunJJ, et al.: Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World J Gastrointest Oncol, 2016; 8:555–562.
26.
ZhangY, ZhouGQ, LiuX, et al.: Exploration and validation of C-reactive protein/albumin ratio as a novel inflammation-based prognostic marker in nasopharyngeal carcinoma. J Cancer, 2016; 7:1406–1412.
27.
LairdBJ, KaasaS, McMillanDC, et al.: Prognostic factors in patients with advanced cancer: A comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res, 2013; 19:5456–5464.
28.
MiuraT, MatsumotoY, HamaT, et al.: Glasgow Prognostic Score predicts prognosis for cancer patients in palliative settings: A subanalysis of the Japan-prognostic assessment tools validation (J-ProVal) study. Support Care Cancer, 2015; 23:3149–3156.
29.
ForrestLM, McMillanDC, McArdleCS, et al.: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer, 2004; 90:1704–1706.
30.
McMillanDC: The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treat Rev, 2013; 39:534–540.
31.
ProctorMJ, MorrisonDS, TalwarD, et al.: A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer, 2011; 47:2633–2641.
32.
LintonA, PondG, ClarkeS, et al.: Glasgow Prognostic Score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer, 2013; 11:423–430.
33.
MoritaT, TsunodaJ, InoueS, et al.: The Palliative Prognostic Index: A scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer, 1999; 7:128–133.
34.
StoneCA, TiernanE, DooleyBA: Prospective validation of the Palliative Prognostic Index in patients with cancer. J Pain Symptom Manage, 2008; 35:617–622.
35.
MaltoniM, ScarpiE, PittureriC, et al.: Prospective comparison of prognostic scores in palliative care cancer populations. Oncologist, 2012; 17:446–454.
36.
ChengWH, KaoCY, HungYS, et al.: Validation of a Palliative Prognostic Index to predict life expectancy for terminally ill cancer patients in a hospice consultation setting in Taiwan. Asian Pac J Cancer Prev, 2012; 13:2861–2866.
37.
MoritaT, TsunodaJ, InoueS, et al.: Improved accuracy of physicians' survival prediction for terminally ill cancer patients using the Palliative Prognostic Index. Palliat Med, 2001; 15:419–424.
38.
StielS, BertramL, NeuhausS, et al.: Evaluation and comparison of two prognostic scores and the physicians' estimate of survival in terminally ill patients. Support Care Cancer, 2010; 18:43–49.
39.
GlareP, EychmuellerS, VirikK: The use of the Palliative Prognostic Score in patients with diagnoses other than cancer. J Pain Symptom Manage, 2003; 26:883–885.
40.
GlareP, VirikK: Independent prospective validation of the PaP score in terminally ill patients referred to a hospital-based palliative medicine consultation service. J Pain Symptom Manage, 2001; 22:891–898.
41.
GlarePA, EychmuellerS, McMahonP: Diagnostic accuracy of the Palliative Prognostic Score in hospitalized patients with advanced cancer. J Clin Oncol, 2004; 22:4823–4828.
42.
CaraceniA, NanniO, MaltoniM, et al.: Impact of delirium on the short term prognosis of advanced cancer patients. Cancer, 2000; 89:1145–1149.
43.
NaylorC, CerqueiraL, Costa-PaivaLHS, et al.: Survival of women with cancer in palliative care: Use of the Palliative Prognostic Score in a population of Brazilian women. J Pain Symptom Manage, 2010; 39:69–75.
44.
ChouWC, KaoCY, WangPN, et al.: The application of the Palliative Prognostic Index, Charlson Comorbidity Index, and Glasgow Prognostic Score in predicting the life expectancy of patients with hematologic malignancies under palliative care. BMC Palliat Care, 2015; 14:18.
45.
PirovanoM, MaltoniM, NanniO, et al.: A new Palliative Prognostic Score: A first step for the staging of terminally ill cancer patients. J Pain Symptom Manage, 1999; 17:231–239.
46.
MaltoniM, NanniO, PirovanoM, et al.: Successful validation of the Palliative Prognostic Score in terminally ill cancer patients. J Pain Symptom Manage, 1999; 17:240–247.
47.
HarrellFE Jr, LeeKL, MarkDB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med, 1996; 15:361–387.
48.
FaircloughE, CairnsE, HamiltonJ, et al.: Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin Med (Lond), 2009; 9:30–33.
49.
RanzaniOT, ZampieriFG, ForteDN, et al.: C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. PLoS One, 2013; 8:e59321.
50.
GagnonB, AbrahamowiczM, XiaoY, et al.: Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer. Br J Cancer, 2010; 102:1113–1122.
51.
ArrietaO, Michel OrtegaRM, Villanueva-RodríguezG, et al.: Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: A prospective study. BMC Cancer, 2010; 10:50.
52.
KochA, FohlinH, SorensonS: Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol, 2009; 4:326–332.
53.
WilopS, CrysandtM, BendelM, et al.: Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Onkologie, 2008; 31:665–670.
54.
MahmoudFA, RiveraNI: The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep, 2002; 4:250–255.
55.
LiuZ, JinK, GuoM, et al.: Prognostic value of the CRP/Alb ratio, a novel inflammation-based score in pancreatic cancer. Ann Surg Oncol, 2017; 24:561–568.
56.
ZhangF, YingL, JinJ, et al.: The C-reactive protein/albumin ratio predicts long-term outcomes of patients with operable non-small cell lung cancer. Oncotarget, 2017; 8:8835–8842.
57.
MiyazakiT, YamasakiN, TsuchiyaT, et al.: Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small-cell lung cancer in elderly patients. Surg Today, 2017; 47:836–843.
58.
AmanoK, MaedaI, MoritaT, et al.: Clinical implications of C-reactive protein as a prognostic marker in advanced cancer patients in palliative care settings. J Pain Symptom Manage, 2016; 51:860–867.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
